New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight management, boost metabolism, and curb cravings, Nixol has positioned itself as a natural, vegan-friendly alternative to traditional weight loss solutions. Unlike products that rely on synthetic stimulants or restrictive diets, Nixol leverages a blend of carefully selected, science-backed ingredients to promote sustainable fat reduction and overall well-being. This article provides an in-depth exploration of Nixol’s launch, its formulation, claims, scientific backing, customer feedback, and the broader context of its market entry, while critically examining its potential effectiveness and limitations. Visit Official Website
VANCOUVER, BC, July 2, 2025 /CNW/ - NGEx Minerals Ltd. ("NGEx", "NGEx Minerals" or the "Company") (TSX: NGEX) (OTCQX: NGXXF) is pleased to announce additional...
CANADIAN GOVERNMENT'S COMMITMENT TO MEET NATO SPENDING TARGET BY DEVELOPING CRITICAL MINERALS COULD DELIVER MAJOR BENEFITS TO ASHRAM
MONTREAL, July 2, 2025 /CNW/ -- Commerce...
TABER, ALBERTA, July 01, 2025 (GLOBE NEWSWIRE) -- FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. FSI is also increasing its presense in the food and nutrition supplement manufacturing markets. Today the Company announces it has received payment of US$2.5million for assisting in developing a new food grade product.
CHANGZHOU, China, July 1, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions...
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.
In this 2025 public health alignment update, GlucoTru Pro emphasizes the growing consumer awareness of natural metabolic support strategies, including non-synthetic approaches to managing blood pressure, blood sugar, and overall wellness. This release provides new insights into public commentary themes, recent transparency in ingredient sourcing, and the alignment of the GlucoTru Pro formula with broader non-pharmaceutical health discussions.
VADUZ, Liechtenstein, July 1, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device...
WAYNE, Pa., June 30, 2025 /PRNewswire/ -- Ecovyst Inc. (NYSE: ECVT), a leading integrated and innovative global provider of advanced materials, specialty catalysts, virgin...
CLAYTON, Mo., June 30, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) and K2 Pure Solutions are pleased to announce an expansion of their strategic partnership...
/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR...
The 2025 update explores how evolving consumer interest in brain fog, coffee-enhanced wellness routines, and ingredient transparency is shaping the future of cognitive support.
The 2025 update explores how evolving consumer interest in brain fog, coffee-enhanced wellness routines, and ingredient transparency is shaping the future of cognitive support.
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.
CLAYTON, Mo., June 26, 2025 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that on Tuesday, July 29, 2025, at 9:00 a.m. Eastern time, Olin's...